Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E - PubMed (original) (raw)
Comparative Study
. 1994 Jan 21;269(3):2324-35.
Affiliations
- PMID: 8294490
Free article
Comparative Study
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
H V de Silva et al. J Biol Chem. 1994.
Free article
Abstract
Overexpression of human apolipoprotein (apo) C-III in the plasma of transgenic mice results in hypertriglyceridemia, with up to a 20-fold elevation in plasma triglyceride. Nearly all of the triglyceride accumulates in the d < 1.006 g/ml lipoprotein fraction, which consists predominantly of apoB48-containing particles having a low apoE:apoB48 ratio in contrast to normal mice. The transgenic and nontransgenic d < 1.006 g/ml lipoproteins are similar in size, and they are equivalent substrates for lipoprotein lipase in vitro. Total apoB100 levels are similar in transgenic and normal plasma, but apoB48 levels are increased in transgenic mice. The transgenic d < 1.006 g/ml particles are poor competitors for the binding of low density lipoproteins to the low density lipoprotein receptor in vitro, which is corrected by the addition of exogenous apoE. The rate of clearance of labeled chylomicron remnants in apoC-III-transgenic mice was about half that in nontransgenic mice. The lipoprotein alterations are accompanied by up to a 5-fold increase in circulating nonesterified fatty acids, which may be the cause of fatty livers and increased liver triglyceride production also observed in the transgenic mice. These observations indicate that the primary defect leading to hypertriglyceridemia in apoC-III overexpressers is an impaired clearance of apoB48 remnants due to apoE insufficiency. Therefore, transgenic mice that overexpressed human apoE were cross-bred with the apoC-III overexpressers. Transgenic progeny that produced both human apoE and human apoC-III had normal levels of plasma triglyceride and normal amounts of apoB48 remnants. Thus, our studies suggest that a function of apoC-III is to modulate the apoE-mediated clearance of lipoproteins, and that the concentration of apoC-III relative to apoE is a key determinant of triglyceride levels in plasma.
Similar articles
- Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.
Conde-Knape K, Okada K, Ramakrishnan R, Shachter NS. Conde-Knape K, et al. J Lipid Res. 2004 Dec;45(12):2235-44. doi: 10.1194/jlr.M400185-JLR200. Epub 2004 Sep 1. J Lipid Res. 2004. PMID: 15342689 - Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Aalto-Setälä K, et al. J Lipid Res. 1996 Aug;37(8):1802-11. J Lipid Res. 1996. PMID: 8864964 - The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
Sacks FM. Sacks FM. Curr Opin Lipidol. 2015 Feb;26(1):56-63. doi: 10.1097/MOL.0000000000000146. Curr Opin Lipidol. 2015. PMID: 25551803 Free PMC article. Review. - Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
Jong MC, Havekes LM. Jong MC, et al. Int J Tissue React. 2000;22(2-3):59-66. Int J Tissue React. 2000. PMID: 10937355 Review.
Cited by
- Role of APOC3 3238C/G, APOB 12669G/A and SCARB1 1050C/T polymorphisms, their expression in patients of HIV-associated lipodystrophy.
Singh H, Shyamveer, Jori C, Mahajan SD, Aalinkeel R, Kaliyappan K, Bhattacharya M, Parvez MK, Al-Dosari MS. Singh H, et al. Heliyon. 2024 May 1;10(9):e30519. doi: 10.1016/j.heliyon.2024.e30519. eCollection 2024 May 15. Heliyon. 2024. PMID: 38742060 Free PMC article. - Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Yanai H, et al. Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942. Int J Mol Sci. 2023. PMID: 37762244 Free PMC article. Review. - Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM. Furtado JD, et al. Arterioscler Thromb Vasc Biol. 2022 Feb;42(2):227-237. doi: 10.1161/ATVBAHA.121.317181. Epub 2021 Dec 23. Arterioscler Thromb Vasc Biol. 2022. PMID: 34937388 Free PMC article. Clinical Trial. - Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis.
Whitacre BE, Howles P, Street S, Morris J, Swertfeger D, Davidson WS. Whitacre BE, et al. J Lipid Res. 2022 Jan;63(1):100157. doi: 10.1016/j.jlr.2021.100157. Epub 2021 Dec 1. J Lipid Res. 2022. PMID: 34863862 Free PMC article. - Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.
Yan H, Niimi M, Matsuhisa F, Zhou H, Kitajima S, Chen Y, Wang C, Yang X, Yao J, Yang D, Zhang J, Murakami M, Nakajima K, Wang Y, Liu E, Liang J, Chen YE, Fan J. Yan H, et al. Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2095-2107. doi: 10.1161/ATVBAHA.120.314368. Epub 2020 Aug 6. Arterioscler Thromb Vasc Biol. 2020. PMID: 32757647 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous